Active refractory juvenile idiopathic arthritis: Treatment with infliximab. Efficacy and safety

Fabrizia Corona, M. Scarazatti, L. Dell'Era, M. Beltramelli, V. Carnelli, M. Bardare

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives. To evaluate efficacy and safety of infliximab (Remicade) in patients affected by severe Juvenile Idiopathic Arthritis (JIA) unresponsive to traditional DMARDs. Methods. Nine patients were treated with infliximab (3 mg/kg ev) on days 0, 15, 45 and then every two months. Patients who had a 30% improvement in at least three of the six variables evaluated, with no more than one indicator worsening by more than 30%, were considered responders. Results. Six out of nine patients satisfied the criteria for improvement. Two patients experienced adverse events that required withdrawal from the study. Conclusions. These data confirm infliximab as an effective treatment for refractory JIA.

Original languageEnglish
Pages (from-to)165-168
Number of pages4
JournalItalian Journal of Pediatrics
Volume30
Issue number3
Publication statusPublished - Jun 2004

Keywords

  • Anti-TNFα
  • Juvenile Idiopathic Arthritis
  • Monoclonal antibody

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Active refractory juvenile idiopathic arthritis: Treatment with infliximab. Efficacy and safety'. Together they form a unique fingerprint.

Cite this